Navigation Links
Debiopharm Moves Towards a New 6-Month Formulation of Decapeptyl(R) to Further Help Prostate Cancer Patients
Date:9/25/2008

LAUSANNE, Switzerland, September 25 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, announces the filing of an application with the European Agencies for the approval of its new 6-month formulation of Decapeptyl(R) (triptorelin pamoate 22.5 mg), a luteinizing hormone releasing hormone (LHRH) agonist for the treatment of locally advanced or metastatic, hormone-dependent prostate cancer. Once approved, Decapeptyl(R) 6-month formulation will be marketed by Debiopharm's partners, such as Ipsen in most European Union countries.

"This submission in Europe of our first 6-month-formulation for the treatment of prostate cancer is another demonstration of Debiopharm's commitment to supporting and enhancing the life of cancer patients. With an injection every 24 weeks, patients will benefit from increased convenience and comfort," said Kamel Besseghir, CEO of Debiopharm S.A. "Furthermore, upon approval, our newly built production line will be ready to manufacture the drug for worldwide distribution."

The MAA for Decapeptyl(R) 6 month formulation is supported by data from a phase III study on the efficacy and safety of two consecutive injections of triptorelin 6-month formulation in 120 patients with advanced prostate cancer. The results showed that 97.5% of patients achieved castrate levels of serum testosterone 28 days after the first injection and that 93% of the patients maintained serum testosterone levels below castrate level (defined as < 1.735 nmol/L or 50 ng/dL) from week 8 to 48. These efficacy results are similar to those obtained previously with repeated administrations of the 1- and 3-month formulations of triptorelin.

About Decapeptyl(R)

Triptorelin was licensed-in from Tulane University in 1982. Debiopharm developed and submitted a 1- and 3-month sustained release formulation of triptorelin pamoate in Europe and
'/>"/>

SOURCE Debiopharm Group
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Debiopharm and EPFL Sign Research Project Agreement to Identify Inhibitors of Signalling Pathways Controlling Cell Fate for Cancer Treatment
2. Arriva Pharmaceuticals Moves Forward to Phase 2b Development of Lead Inhaled Protein rAAT Replacement Therapy for Hereditary Emphysema
3. Trellis(R) Catheter Removes Blood Clots Quickly, Restoring Blood Flow in 771 Deep Vein Thrombosis (DVT) Patients
4. Neutropenia: Biosimilar Product from India Moves One Step Closer to European Market
5. Roche Moves Investigational Diabetes Drug, Taspoglutide, Into Phase III Clinical Trials
6. CellCept(R) and a Reduced Level of CNI Shows Trend Towards Preservation of Kidney Function Versus a Standard-Dose CNI
7. Clinical Update - Decapeptyl(R)/Trelstar(R) 6-Month Formulation in Advanced Prostate Cancer
8. New Trial Presented at AAAAI Reports that the Growth of Children 2-5 Years Old with Year-Round Allergic Rhinitis Continued According to Normal Age-Adjusted Distribution Over a 6-Month Treatment with Nasacort AQ
9. ISTA Pharmaceuticals Presents Results from Two Phase III Clinical Trials of Xibrom(TM) QD (Once-daily) Formulation at the American Academy of Ophthalmology Annual Meeting
10. Kibow Biotech Obtains Australian, Chinese and Indian Patents Protecting the Composition and Basic Technology Behind Its Oral Probiotic Formulation for Chronic Kidney Failure
11. ISTA Pharmaceuticals Announces Results of Clinical Trial of Xibrom(TM) QD (Once-Daily) Formulation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013 Amgen (NASDAQ: ... th Annual  Healthcare Conference on Thursday, May 30, 2013, ... , beginning at 9:20 a.m. Eastern Daylight Time. ... Amgen, will present at the conference. Live audio of the ... website, www.amgen.com , under Investors. A replay of the ...
(Date:5/23/2013)... 23, 2013  MGC Diagnostics Corporation (NASDAQ: ... company, today scheduled a conference call to discuss its ... 2013, ended April 30, 2013. The call will be ... The Company will report financial results for the second ... on Thursday, May 30, 2013. (Logo: ...
(Date:5/23/2013)... , May 23, 2013 More than ... may not benefit from chemotherapy and still have excellent ... launch of one of the largest sources of online ... website and interactive Facebook page provide recently diagnosed women ... can safely avoid chemotherapy. "We anticipate these ...
Breaking Medicine Technology:MGC Diagnostics Corporation to Report Second Quarter Fiscal 2013 Financial Results on Thursday, May 30, 2013 2Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 2Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 3
... Nov. 4, 2010 Decision Resources, one of the ... healthcare issues, finds that biosimilar erosion of branded erythropoietin ... more rapid and more complete in the United States ... ESAs entered the European market in 2007. According to ...
... 4, 2010 NuView Life Sciences, Inc ("NuView"), ... proprietary target specific biomarkers for utilization with Positron ... its applications for the Qualifying Therapeutic Discovery Project ... The grants totaling just over $1.2 million dollars ...
Cached Medicine Technology:Biosimilar Erosion of Branded ESA Market Share Will be More Rapid in the U.S. Than in Europe 2NuView Life Sciences Awarded Grants Under the Patient Protection and Affordable Care Act of 2010 2
(Date:5/24/2013)... Coral Springs, FL (PRWEB) May 24, 2013 ... to present May air dates for Charlotte, North Carolina. It ... home to many Fortune 500 companies. The city is populated ... top-notch healthcare organizations which cover residents in both North and ... program about all things medically-related can tune into WAXN-TV 64 ...
(Date:5/24/2013)... GA (PRWEB) May 24, 2013 CBT News.com ... Sales. Gonter joins the web-based retail automotive industry news organization ... , “I’m excited to join a group that’s so ... perfect example of how online video content is on the ... in the motorcycle business and segued into advertising at Cycle ...
(Date:5/24/2013)... Electric™ Energy Straws, an exciting new brand of ... and will be the lead sponsor on Munoz’s Chevy #26 ... Speedway. Munoz, who is part of Andretti Autosports’ fantastic five ... race, qualifying to be named the 2013 Indy 500 Fastest ... race. , While Munoz is grabbing headlines around the ...
(Date:5/24/2013)... American International College of Arts and ... agreement with Old Dominion University (ODU) that ... , The program will permit ODU students ... cell biology course, taught by AICASA’s faculty, for three ... of Antigua (AUA) College of Medicine , students will ...
(Date:5/24/2013)... Texas (PRWEB) May 24, 2013 ... range of products used outside the central laboratory, ... by a healthcare practitioner or by consumers. This ... coagulation, fertility and pregnancy, infectious and cardiovascular disease ... areas such as critical care, surgical and emergency ...
Breaking Medicine News(10 mins):Health News:Health Briefs TV Presents May Air Dates for Charlotte, North Carolina 2Health News:Unistraw Electric™ Energy Straw Chevy Car Powers Indianapolis 500 Rookie Driver Carlos Munoz 2Health News:Unistraw Electric™ Energy Straw Chevy Car Powers Indianapolis 500 Rookie Driver Carlos Munoz 3Health News:AICASA Signs Articulation Agreement with Old Dominion University to Create Study Abroad Program 2Health News:Point of Care Diagnostics Market (POC) Analysis and 5 Year Forecast in New Research Report at ReportsnReports.com 2Health News:Point of Care Diagnostics Market (POC) Analysis and 5 Year Forecast in New Research Report at ReportsnReports.com 3
... Practice Manager Notes Ease of Use, Time Savings, ... Healthcare, Inc. has,announced that West Michigan Orthopaedics, a ... is moving to the Intergy by Sage,practice management ... The three-physician group had been on The ...
... PARK, N.C., Dec. 11 Quintiles,Transnational Corp. today ... President and General Counsel., Previously Senior Vice ... Quintiles in 1998 as Vice President, European,Legal Affairs., ... and the clinical,research industry, having served the company ...
... Influenza Vaccination Into the New Year, BETHESDA, ... season,in full swing, getting vaccinated against influenza, commonly ... keep you and your family healthy. Too many,people ... in October and,November, but the National Foundation for ...
... Dec. 11 Amedica Corporation, an,orthopedic implants company ... the U.S. Food and Drug Administration,has granted a ... spinal implant., The Valeo VBR spinal implant ... surgical correction and stabilization of the thoracolumbar spine.,The ...
... Advance(R) and Similac(R) Isomil(R) Advance(R) Formulas Now ... Available in Nipple-Ready 8-Fluid-Ounce Bottles, COLUMBUS, Ohio, Dec. ... moms commissioned by Abbott,s Similac brand, packing the,diaper bag ... 30 minutes.,Nearly all moms surveyed (98 percent) agree that ...
... cells (progenitor cells) to treat the damage to cardiac ... Emory University School of Medicine. , The study investigators--Emory ... update their colleagues on its progress at the American ... "This is one of the first trials where patients ...
Cached Medicine News:Health News:West Michigan Orthopaedics Migrates to Intergy by Sage Practice Management System 2Health News:West Michigan Orthopaedics Migrates to Intergy by Sage Practice Management System 3Health News:Don't Let Influenza Ruin Your Holidays - Get Vaccinated 2Health News:Don't Let Influenza Ruin Your Holidays - Get Vaccinated 3Health News:Amedica Receives FDA Special 510(k) Clearance for its Valeo(TM) Ceramic Spinal Implant 2Health News:Similac(R) Survey Finds New Moms Want Convenient, Time-Saving Baby Products 2Health News:Similac(R) Survey Finds New Moms Want Convenient, Time-Saving Baby Products 3Health News:Adult stem cell heart attack study updated at American Society for Hematology Meeting 2
... H-1200 Fast Flow Fluid Warmer, a new generation ... the existing Level 1 Fast Flow Fluid Warmer ... Fluid Warmer incorporates the features of integrated air ... deliver warm fluids as fast as 1,000 ml/minute ...
Futuremeds Astotherm Plus Blood and Fluid Warmers meet American Blood Bank and ECRI standards., ,Astotherm is a durable warmer you can rely on for many years....
... Flexible excellence for patients and clinicians., ... the Aestiva/5 anesthesia system, the Aestiva/5 MRI ... anesthesia systems with a fully functional, integrated ... (300 Gauss, 1.5 T active shielded magnet), ...
... meeting today's and tomorrow's needs in anesthesia procedures., ... solutions in its field today. This compact system ... revolving arm holds the complete user interface. A ... that there is less need to move the ...
Medicine Products: